nach oben

19.02.2025 | Infektiologie

Ambulante parenterale antiinfektive Therapie (APAT)

verfasst von: Dr. med. Liseth Gehlen, Clara Lehmann

Erschienen in: Wiener klinisches Magazin

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die ambulante parenterale antiinfektive Therapie (APAT) bezeichnet die Applikation intravenöser antiinfektiver Substanzen außerhalb des Krankenhauses. Diese Vorgehensweise ermöglicht eine Verkürzung der Krankenhausliegedauer und reduziert so das damit verbundene Risiko nosokomialer Infektionen. Gleichzeitig trägt die APAT dazu bei, die Lebensqualität der Patient:innen zu verbessern. Im vorliegenden Beitrag werden die Grundzüge der APAT beschrieben. Organisation, Planung und konkrete Durchführung werden erläutert.

Rucker RW, Gunyon Harrison M (1974) Outpatient intravenous medications in the management of cystic fibrosis. Pediatrics 54(3):358–360. https://doi.org/10.1542/peds.54.3.358CrossRefPubMed

Williams DN, Baker CA, Kind AC, Sannes MR (2015) The history and evolution of outpatient parenteral antibiotic therapy (OPAT). Int J Antimicrob Agents 46(3):307–312. https://doi.org/10.1016/j.ijantimicag.2015.07.001CrossRefPubMed

Norris AH, Shrestha NK, Allison GM, Keller SC, Bhavan KP, Zurlo JJ, Hersh AL, Gorski LA, Bosso JA, Rathore MH, Arrieta A, Petrak RM, Shah A, Brown RB, Knight SL, Umscheid CA (2019) 2018 infectious diseases society of america clinical practice guideline for the management of outpatient parenteral antimicrobial therapy. Clin Infect Dis 68(1):e1–e35. https://doi.org/10.1093/cid/ciy745CrossRefPubMed

CRG Publishing and Infectious Diseases Society of America (2016) OPATeHandbook. https://www.idsociety.org/opat-ehand-book/. Zugegriffen: 18. Dez. 2023

Lai T, Thiele H, Rogers BA, Hillock N, Adhikari S, McNamara A, Rawlins M (2023) Exploring the advancements of Australian OPAT. Ther Adv Infect Dis 10:20499361231199582. https://doi.org/10.1177/20499361231199582CrossRefPubMedPubMedCentral

Rieg S, Küpper MF (2016) Infectious diseases consultations can make the difference: a brief review and a plea for more infectious diseases specialists in Germany. Infection 44:159–166. https://doi.org/10.1007/s15010-016-0883-1CrossRefPubMed

Wai AO, Frighetto L, Marra CA, Chan E, Jewesson PJ (2000) Cost analysis of an adult outpatient parenteral antibiotic therapy (OPAT) programme. A Canadian teaching hospital and ministry of health perspective. PharmacoEconomics 18(5):451–457. https://doi.org/10.2165/00019053-200018050-00004CrossRefPubMed

Durojaiye OC, Bell H, Andrews D, Ntziora F, Cartwright K (2018) Clinical efficacy, cost analysis and patient acceptability of outpatient parenteral antibiotic therapy (OPAT): a decade of Sheffield (UK) OPAT service. Int J Antimicrob Agents 51(1):26–32. https://doi.org/10.1016/j.ijantimicag.2017.03.016CrossRefPubMed

Staples JA, Ho M, Ferris D, Hayek J, Guiping L, Tran KC, Sutherland JM (2022) Outpatient versus inpatient intravenous antimicrobial therapy: a population-based observational cohort study of adverse events and costs. Clin Infect Dis 75(11):1921–1929. https://doi.org/10.1093/cid/ciac298CrossRefPubMed

10.

Karimaghaei S, Rao A, Chijioke J, Finch N, Nigo M (2022) Characteristics, safety and cost-effectiveness analysis of self-administered outpatient parenteral antibiotic therapy via a disposable elastomeric continuous infusion pump at two county hospitals in Houston, Texas, United States. J Clin Pharm Ther 47(2):211–217. https://doi.org/10.1111/jcpt.13550CrossRefPubMed

11.

Dimitrova M, Gilchrist M, Seaton RA (2021) Outpatient parenteral antimicrobial therapy (OPAT) versus inpatient care in the UK: a health economic assessment for six key diagnoses. BMJ Open 11(9):e49733. https://doi.org/10.1136/bmjopen-2021-049733CrossRefPubMedPubMedCentral

12.

Wee LE, Sundarajoo M, Quah WF, Farhati A, Huang JY, Chua YY (2020) Health-related quality of life and its association with outcomes of outpatient parenteral antibiotic therapy. Eur J Clin Microbiol Infect Dis 39(4):765–772. https://doi.org/10.1007/s10096-019-03787-6CrossRefPubMed

13.

Durojaiye OC, Jibril I, Kritsotakis EI (2022) Effectiveness of telemedicine in outpatient parenteral antimicrobial therapy (Tele-OPAT): a systematic review. J Telemed Telecare. https://doi.org/10.1177/1357633X221131842CrossRefPubMed

14.

Scholten N, Leisse C, Brandes V, Oberröhrmann C, Ihle P, Peter S, Hagemeier A, Hellmich M, Lindemann CH, Samel C, Pfaff H, Lehmann C (2022) Outpatient parenteral antimicrobial therapy in Germany: a prospective cohort study protocol. BMJ Open 12(11):e61417. https://doi.org/10.1136/bmjopen-2022-061417CrossRefPubMedPubMedCentral

15.

Chapman ALN, Patel S, Horner C, Green H, Guleri A, Hedderwick S, Snape S, Statham J, Wilson E, Gilchrist M, Seaton RA (2019) Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK. JAC Antimicrob Resist 1(2):dlz26. https://doi.org/10.1093/jacamr/dlz026CrossRefPubMedPubMedCentral

16.

https://innovationsfonds.g-ba.de/downloads/beschluss-dokumente/435/2023-08-16_K-APAT.pdf. Zugegriffen: 29. Nov. 2023

17.

Seaton RA, Barr DA (2013) Outpatient parenteral antibiotic therapy: principles and practice. Eur J Intern Med 24(7):617–623. https://doi.org/10.1016/j.ejim.2013.03.014CrossRefPubMed

18.

Quintens C, Steffens E, Jacobs K, Schuermans A, Van Eldere J, Lagrou K, De Munter P, Derdelinckx I, Peetermans WE, Spriet I (2020) Efficacy and safety of a Belgian tertiary care outpatient parenteral antimicrobial therapy (OPAT) program. Infection 48(3):357–366. https://doi.org/10.1007/s15010-020-01398-4CrossRefPubMed

19.

Gardiol C, Voumard R, Cochet C et al (2016) Setting up an outpatient parenteral antimicrobial therapy (OPAT) unit in Switzerland: review of the first 18 months of activity. Eur J Clin Microbiol Infect Dis 35:839–845. https://doi.org/10.1007/s10096-016-2606-zCrossRefPubMed

20.

Terhalle E et al (2020) Dtsch Med Wochenschr 145(23):1688–1694. https://doi.org/10.1055/a-1114-3990CrossRefPubMed

21.

Molina KC, Miller MA, Mueller SW, Van Matre ET, Krsak M, Kiser TH (2022) Clinical pharmacokinetics and pharmacodynamics of dalbavancin. Clin Pharmacokinet 61(3):363–374. https://doi.org/10.1007/s40262-021-01088-wCrossRefPubMed

22.

https://www.g-ba.de/downloads/39-261-5978/2023-04-20_AM-RL-XII_Dalbavancin_2023-R-001.pdf. Zugegriffen: 26. Jan. 2023

23.

https://www.g-ba.de/downloads/92-975-6887/2023-08-01_Bewertung-Therapiekosten-Patientenzahlen-IQWiG_Dalbavancin_D-971.pdf. Zugegriffen: 26. Jan. 2023

24.

Ingram PR, Kilgarriff S, Grzelak M, Jackson G, Carr P, Boan P, Italiano C, Dyer J, Raby E (2022) Risk factors for catheter related thrombosis during outpatient parenteral antimicrobial therapy. J Vasc Access 23(5):738–742. https://doi.org/10.1177/11297298211009361CrossRefPubMed

25.

Underwood J, Marks M, Collins S, Logan S, Pollara G (2019) Intravenous catheter-related adverse events exceed drug-related adverse events in outpatient parenteral antimicrobial therapy. J Antimicrob Chemother 74(3):787–790. https://doi.org/10.1093/jac/dky474CrossRefPubMed

26.

Shah A, Petrak R, Fliegelman R, Shrestha N, Genève A, Zurlo J, Parker S, Poretz D, McKinsey D, Dougherty M, Martinelli L, Mathur A, Rodriguez A, Smith MW (2019) Infectious diseases specialty intervention is associated with better outcomes among privately insured individuals receiving outpatient parenteral antimicrobial therapy. Clin Infect Dis 68(7):1160–1165. https://doi.org/10.1093/cid/ciy674CrossRefPubMed

Titel: Ambulante parenterale antiinfektive Therapie (APAT)
verfasst von: Dr. med. Liseth Gehlen
Clara Lehmann
Publikationsdatum: 19.02.2025
Verlag: Springer Vienna
Erschienen in: Wiener klinisches Magazin
Print ISSN: 1869-1757
Elektronische ISSN: 1613-7817
DOI: https://doi.org/10.1007/s00740-025-00552-8

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten